Pfizer (PFE)
25.23  -0.33 (-1.29%)

Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions.

SummaryNewsPress ReleasesChartHistorical
Previous Close25.56
Open25.45
Bid25.22
Ask25.23
Day's Range25.18 - 25.50
52 Week Range24.48 - 31.54
Volume42,542,582
Market Cap141.46B
PE Ratio (TTM)33.64
EPS (TTM)0.8
Dividend & Yield1.680 (6.66%)
1 Month Average Volume50,565,789

News & Press Releases

10 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · December 4, 2024
Pfizer's New Chief Scientific Officer Charts R&D Vision For High And Low-Risk Investmentsbenzinga.com
Pfizer's Chris Boshoff outlines plans to prioritize high-return projects, with a focus on obesity, Oncology, and oral GLP-1 therapies, amid Q3 growth.
Via Benzinga · December 3, 2024
Valneva's Chikungunya Shot Shows Strong, Long-Lasting Antibody Persistence At Three Years, Comparable In Older And Younger Adultsbenzinga.com
Valneva reports long-lasting antibody persistence in its chikungunya vaccine three years post-dose, supporting its global approvals and expansion efforts.
Via Benzinga · December 3, 2024
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominancebenzinga.com
Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a $100B market.
Via Benzinga · December 3, 2024
3 Magnificent Dividend Stocks With Yields Above 6% to Buy in Decemberfool.com
Via The Motley Fool · December 2, 2024
Is Pfizer Stock in Trouble?fool.com
Via The Motley Fool · November 28, 2024
(PFE) - Analyzing Pfizer's Short Interestbenzinga.com
Via Benzinga · November 25, 2024
10 Health Care Stocks With Whale Alerts In Today's Sessionbenzinga.com
Via Benzinga · December 2, 2024
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Laterfool.com
Via The Motley Fool · December 1, 2024
Should You Buy More Shares Of Your Loser Stocks?talkmarkets.com
This is one of the most difficult questions in investing because it’s filled with emotions. Long-term investors tend to stay in losing stocks to try and “make it back” to their breakeven level.
Via Talk Markets · December 1, 2024
Is This a New Reason to Buy Pfizer Stock Hand Over Fist?fool.com
Via The Motley Fool · November 29, 2024
Black Friday Sale for Income Investors: These 3 Ultra-High-Yield Dividend Stocks Are Bargain Buysfool.com
Via The Motley Fool · November 29, 2024
Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
Here's why Eli Lilly, Pfizer, and AstraZeneca are biotech stocks worth considering, with strong pipelines and growth potential beyond vaccines.
Via MarketBeat · November 28, 2024
Billionaires Are Buying Up Beaten-Down Pfizer Stock. Should You Follow Their Lead?fool.com
Via The Motley Fool · November 27, 2024
2 Generic Drug Stocks Ready to Surge in 2025
Explore how Teva Pharmaceuticals and Viatris are leading the generics industry with strong growth, robust pipelines, and strategies for 2025 success.
Via MarketBeat · November 27, 2024
Should You Buy the 3 Highest-Paying Dividend Stocks in the S&P 500?fool.com
Via The Motley Fool · November 26, 2024
2 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Incomefool.com
Via The Motley Fool · November 26, 2024
Advocating for Justice: Supporting Individuals in the Depo-Provera Litigation
Rhode Island - Marin, Barrett, and Murphy Law Firm, a leading advocate for victims of corporate negligence, is spearheading efforts to support individuals impacted by the long-term use of the injectable contraceptive Depo-Provera. This medication, manufactured by Pfizer, has been linked to severe health consequences, including the development of brain tumors, particularly meningiomas. Victims are seeking justice for the alleged failure of Pfizer to adequately warn consumers of these risks, with the Firm providing experienced legal representation around the Depo-Provera lawsuit.
Via Get News · November 26, 2024
Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugsbenzinga.com
The Biden Administration's proposal expands Medicare and Medicaid coverage for anti-obesity drugs, cutting costs for millions while addressing the obesity crisis.
Via Benzinga · November 26, 2024
BridgeBio Catapults After Snagging Approval For Pfizer-Rivaling Heart Druginvestors.com
BridgeBio will sell its drug at a slightly lower wholesale acquisition cost compared to Pfizer's blockbuster, Vyndaqel.
Via Investor's Business Daily · November 25, 2024
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Marketbenzinga.com
FDA approves BridgeBio's Attruby for ATTR-CM. Phase 3 results highlight its effectiveness in reducing cardiovascular risks and improving life quality.
Via Benzinga · November 25, 2024
3 Dividend Stocks That Are Screaming Buys in Novemberfool.com
Political uncertainty has created buying opportunities among blue-chip healthcare stocks with big-time dividends.
Via The Motley Fool · November 23, 2024
Weight-Loss Drugs Don't Seem To Impress RFK Jr. Should Eli Lilly, Novo Nordisk Investors Worry?investors.com
Robert F. Kennedy hasn't overtly commented on how he would handle GLP-1 drugs. But there are hints.
Via Investor's Business Daily · November 22, 2024
Pfizer Stock Drops 10% In November On News Of Kennedy's HHS Nominationbenzinga.com
Pfizer shares are trading lower by 10% in November. President-elect Donald Trump last week announced his intention to nominate Robert F. Kennedy Jr. to lead the HHS.
Via Benzinga · November 22, 2024
2 Beaten-Down Healthcare Stocks to Buy Hand Over Fistfool.com
Via The Motley Fool · November 21, 2024